# Endo Hirsutism No Preference Antiandrogen Avoid Flutamide

> For women with patient-important hirsutism despite cosmetic measures who have suboptimal response after ≥6 months of oral contraceptive monotherapy, consider adding an antiandrogen; no preference among antiandrogens but avoid flutamide due to its hepatotoxicity risk.

- Skill: `dromlakhani/endo-hirsutism-no-preference-antiandrogen-avoid-flutamide` (Agent Skill)
- Install (CLI): `npx skillmds@latest add dromlakhani/endo-hirsutism-no-preference-antiandrogen-avoid-flutamide`
- Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/endo-hirsutism-no-preference-antiandrogen-avoid-flutamide/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Coding & Dev Tools
- Author: dromlakhani (https://skillmd.com/u/dromlakhani)
- Updated: 2026-09-08
- Page: https://skillmd.com/skills/dromlakhani/endo-hirsutism-no-preference-antiandrogen-avoid-flutamide

---


# No Preference Among Antiandrogens but Avoid Flutamide Due to Hepatotoxicity

## STEP 1 — Gather Information
Collect Ferriman–Gallwey score, menstrual history, signs of hyperandrogenism (acne, alopecia), current contraception use, fertility desires, and prior treatment response (especially OC monotherapy duration and effectiveness). End with: proceed to rule in/out for antiandrogen addition.

## STEP 2 — Rule In / Rule Out
Rule in if patient has patient-important hirsutism despite cosmetic measures, is not seeking pregnancy (or uses reliable contraception), and shows suboptimal response after ≥6 months of oral contraceptive monotherapy; otherwise rule out and continue OC, consider direct hair removal, or reassess adherence.

## STEP 3 — Classify or Stratify
Select an antiandrogen (spironolactone, finasteride, or flutamide) but exclude flutamide due to hepatotoxicity; no preference between spironolactone and finasteride based on efficacy and safety profiles.

## STEP 4 — Decide
Prescribe chosen antiandrogen (e.g., spironolactone 100–200 mg daily or finasteride 2.5–5 mg daily) while continuing oral contraceptive; ensure effective contraception if teratogenic risk applies; schedule follow‑up in 6 months to evaluate hirsutism improvement and adverse effects.

## Clinical Guardrails / Mimics / Pitfalls
Avoid flutamide entirely due to risk of hepatotoxicity and liver failure; do not use antiandrogen monotherapy without reliable contraception because of teratogenic potential; monitor for menstrual irregularities or hyperkalemia with spironolactone; do not initiate antiandrogen in pregnancy or breastfeeding; consider drug interactions (e.g., spironolactone with ACE inhibitors).

## Concrete Clinical Example
A 28‑year‑old woman with PCOS‑related hirsutism (FG score 12) tried OC monotherapy for 8 months with minimal improvement; she desires contraception and is not seeking pregnancy. Flutamide is avoided; spironolactone 100 mg BID is added to her OC. At 6‑month follow‑up, her FG score decreased to 6 and she reports satisfactory hair growth control.

**Source:** Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2018, https://doi.org/10.1210/jc.2018-00241